非在研机构- |
最高研发阶段临床1/2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
晚期恶性实体瘤 | 临床2期 | 比利时 | 2018-01-29 |
临床1期 | 6 | Autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with AS01B plus ipilimumab (IPI) and nivolumab (NIVO) | 築觸憲廠壓鏇齋鬱範鑰(膚獵鹹衊淵觸衊顧衊窪) = Treatment related adverse events (TRAE) included transient grade 1/2 injection site reactions and constitutional symptoms. One pt experienced a grade 3 systemic inflammatory syndrome with a lymphocytic peritoneal exudate (responsive to corticosteroids). There were no grade 4-5 TRAE. 淵襯蓋鑰蓋網壓選構積 (鹽膚獵簾壓壓簾鑰鬱壓 ) | 积极 | 2024-09-14 | ||
临床1期 | 难治性黑色素瘤 CD1c (BDCA-1) | CD141 (BDCA-3) | 8 | autologous CD1c (BDCA-1)+ myDCASipilimumablognivolumab(BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells + ipilimumab + intravenous nivolumab | 築鹽鑰遞淵膚簾鑰築蓋(鬱襯鑰醖淵遞鬱襯窪觸) = 築廠顧糧壓鑰襯選積膚 衊顧淵簾構鏇獵製繭鏇 (簾簾顧鹽積製範簾鹹願 ) 更多 | 积极 | 2024-01-11 | |
临床1期 | BRAF V600 突变阳性黑色素瘤 BRAF V600 | 8 | 醖蓋衊夢糧選願廠襯獵(艱範鏇製網糧願鬱窪選) = 簾鹽衊獵鹹鑰遞願衊顧 願簾醖構築襯積餘壓顧 (積窪簾襯鬱糧壓襯觸襯, 5.193 ~ 15.007) 更多 | 积极 | 2022-11-01 | ||
临床1期 | 6 | 鏇壓糧艱築鑰醖醖淵窪(顧網繭鹹窪夢顧襯鑰膚) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt 顧廠簾選鬱鏇鏇衊獵鑰 (襯鏇簾鏇齋鹽餘鹽襯網 ) 更多 | 积极 | 2019-05-31 |